Ibuprofen‑derived nitric oxide donors with a high affinity to human serum albumin induce cell death in pancreatic cancer cells through a non‑caspase 3/7‑mediated pathway

Nishi,Koji; Arimura,Yoshifumi; Suetsugi,Naho; Beppu,Takuro; Takasaki,Kaho; Tamori,Ayano; Kanda,Ryo; Imoto,Shuhei; Murase,Hirotaka; Tsukigawa,Kenji; Otagiri,Masaki; Yamasaki,Keishi

doi:10.3892/br.2024.1847

Ibuprofen‑derived nitric oxide donors with a high affinity to human serum albumin induce cell death in pancreatic cancer cells through a non‑caspase 3/7‑mediated pathway

Authors:
- Koji Nishi
- Yoshifumi Arimura
- Naho Suetsugi
- Takuro Beppu
- Kaho Takasaki
- Ayano Tamori
- Ryo Kanda
- Shuhei Imoto
- Hirotaka Murase
- Kenji Tsukigawa
- Masaki Otagiri
- Keishi Yamasaki
View Affiliations

Affiliations: Faculty of Pharmaceutical Sciences, Sojo University, Nishi‑ku, Kumamoto 860‑0082, Japan
Published online on: August 29, 2024 https://doi.org/10.3892/br.2024.1847
Article Number: 159

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nitric oxide (NO) has been reported to have a cytotoxic effect on various types of cancer. However, the efficient delivery of NO donors to tumors remains challenging. The present study used ibuprofen, which has a high binding affinity to human serum albumin (HSA). A total of two types of nitrated forms of ibuprofen, 4‑[(nitrooxy)methyl]benzyl 2‑(4‑isobutylphenyl)propanoate [nitrated ibuprofen benzyl linker (NIB)] and 2‑(nitrooxy)ethyl 2‑(4‑isobutylphenyl) propanoate [nitrated ibuprofen ethyl linker (NIE)], were synthesized. It was demonstrated that both NIB and NIE bound to the ibuprofen‑binding site of HSA. Although NOx release was observed from NIB, but not NIE, intracellular NO release was detected from both NIB and NIE, which indicated that the mechanisms of NO release may be different for NIB and NIE. Both NIB and NIE induced concentration‑ and time‑dependent cell death in human pancreatic cancer cells, whereas this cell death was not observed with ibuprofen, which could suggest that these cell death‑inducing effects may be mediated by NO. The non‑specific caspase inhibitor, z‑VAD‑FMK, inhibited cell death induced by NIB and NIE, but activation of caspase 3/7 was not observed. These results suggested that both NIB and NIE induced cell death through a non‑caspase 3/7 pathway. The findings of the present study demonstrated that both NIB and NIE, as NO donors that could be retained in blood, may potentially be useful anti‑cancer agent candidates in the future.

View Figures

View References

1	Cancer Registry and Statistics: Cancer Information Service. National Cancer Center, 2020 (Vital Statistics of Japan). https://ganjoho.jp/en/professional/statistics/table_download.html.
2	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.PubMed/NCBI View Article : Google Scholar
3	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.PubMed/NCBI View Article : Google Scholar
4	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013.PubMed/NCBI View Article : Google Scholar
5	Michl P and Gress TM: Improving drug delivery to pancreatic cancer: Breaching the stromal fortress by targeting hyaluronic acid. Gut. 61:1377–1379. 2012.PubMed/NCBI View Article : Google Scholar
6	Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 21:418–429. 2012.PubMed/NCBI View Article : Google Scholar
7	Ishima Y, Kragh-Hansen U, Maruyama T and Otagiri M: Albumin as a nitric oxide-traffic protein: Characterization, biochemistry and possible future therapeutic applications. Drug Metab Pharmacokinet. 24:308–317. 2009.PubMed/NCBI View Article : Google Scholar
8	Estrada C, Gómez C, Martín C, Moncada S and González C: Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Commun. 186:475–482. 1992.PubMed/NCBI View Article : Google Scholar
9	Kashfi K, Rayyan Y, Qiao LL, Williams JL, Chen J, Del Soldato P, Traganos F, Rigas B and Ryann Y: Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: Evidence of a tissue type-independent effect. J Pharmacol Exp Ther. 303:1273–1282. 2002.PubMed/NCBI View Article : Google Scholar
10	Riganti C, Rolando B, Kopecka J, Campia I, Chegaev K, Lazzarato L, Federico A, Fruttero R and Ghigo D: Mitochondrial-targeting nitrooxy-doxorubicin: A new approach to overcome drug resistance. Mol Pharm. 10:161–174. 2013.PubMed/NCBI View Article : Google Scholar
11	Islam W, Fang J, Imamura T, Etrych T, Subr V, Ulbrich K and Maeda H: Augmentation of the enhanced permeability and retention effect with nitric oxide-generating agents improves the therapeutic effects of nanomedicines. Mol Cancer Ther. 17:2643–2653. 2018.PubMed/NCBI View Article : Google Scholar
12	Ishima Y, Chen D, Fang J, Maeda H, Minomo A, Kragh-Hansen U, Kai T, Maruyama T and Otagiri M: S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects. Bioconjug Chem. 23:264–271. 2012.PubMed/NCBI View Article : Google Scholar
13	Peters T: All about albumin: Biochemistry, genetics, and medical application, acad. Press, Orlando, FL, pp42, 1966.
14	Whittingham JL, Havelund S and Jonassen I: Crystal structure of a prolonged-acting insulin with albumin-binding properties. Biochemistry. 36:2826–2831. 1997.PubMed/NCBI View Article : Google Scholar
15	Kurtzhals P, Havelund S, Jonassen I and Markussen J: Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci. 86:1365–1368. 1997.PubMed/NCBI View Article : Google Scholar
16	Sisson EM: Liraglutide: Clinical pharmacology and considerations for therapy. Pharmacotherapy. 31:896–911. 2011.PubMed/NCBI View Article : Google Scholar
17	Tiessen RG, Castaigne JP, Dreyfus JF, Nemansky M, Kruizinga HH and van Vliet AA: Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. Int J Clin Pharmacol Ther. 46:443–452. 2008.PubMed/NCBI View Article : Google Scholar
18	Ishima Y, Maruyama T, Otagiri M, Chuang VTG and Ishida T: The new delivery strategy of albumin carrier utilizing the interaction with albumin receptors. Chem Pharm Bull (Tokyo). 70:330–333. 2022.PubMed/NCBI View Article : Google Scholar
19	Rahman MH, Yamasaki K, Shin YH, Lin CC and Otagiri M: Characterization of high affinity binding sites of non-steroidal anti-inflammatory drugs with respect to site-specific probes on human serum albumin. Biol Pharm Bull. 16:1169–1174. 1993.PubMed/NCBI View Article : Google Scholar
20	Theodosis-Nobelos P, Papagiouvanis G, Pantelidou M, Kourounakis PN, Athanasekou C and Rekka EA: Design, synthesis and study of nitrogen monoxide donors as potent hypolipidaemic and anti-inflammatory agents. Molecules. 25(19)2019.PubMed/NCBI View Article : Google Scholar
21	Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A and Otagiri M: Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res. 18:520–524. 2001.PubMed/NCBI View Article : Google Scholar
22	Huang Z, Fu J and Zhang Y: Nitric oxide donor-based cancer therapy: Advances and prospects. J Med Chem. 60:7617–7635. 2017.PubMed/NCBI View Article : Google Scholar
23	Saavedra JE, Shami PJ, Wang LY, Davies KM, Booth MN, Citro ML and Keefer LK: Esterase-sensitive nitric oxide donors of the diazeniumdiolate family: In vitro antileukemic activity. J Med Chem. 43:261–269. 2000.PubMed/NCBI View Article : Google Scholar
24	Shi J, Gao W and Shao F: Pyroptosis: Gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci. 42:245–254. 2017.PubMed/NCBI View Article : Google Scholar
25	Gao J, Liu X and Rigas B: Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA. 102:17207–17212. 2005.PubMed/NCBI View Article : Google Scholar
26	Bonavida B, Khineche S, Huerta-Yepez S and Garbán H: Therapeutic potential of nitric oxide in cancer. Drug Resist Updat. 9:157–173. 2006.PubMed/NCBI View Article : Google Scholar
27	Bonavida B, Baritaki S, Huerta-Yepez S, Vega MI, Jazirehi AR and Berenson J: Nitric oxide donors are a new class of anti-cancer therapeutics for the reversal of resistance and inhibition of metastasis. In: Nitric oxide (NO) and cancer: Prognosis, prevention, and therapy. Bonavida B (ed). Springer, New York, NY, pp459-477, 2010.